Clinical Trial Update: A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and pharmacokinetics of inhaled GSK233705 and GW642444 in healthy subjects. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK233705
• GW642444 (GW642444)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED